Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidin (Vidaza) (RELAZA2)
This study is currently recruiting participants.
Verified February 2013 by Dresden University of Technology
Study NCT01462578
Information provided by Dresden University of Technology
First Received on June 22, 2011.
Last Updated on February 28, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
